Dermapharm Holding SE

DMP

DE000A2GS5D8

Pharmaceuticals

Market Closed - Xetra Other stock markets 09:05:25 28/06/2024 pm IST			5-day change	1st Jan Change
36 ^EUR	-1.77%		+0.56%	-14.97%

06/06	Jefferies lowers target for Dermapharm to 51 euros - 'Buy'	DP
06/06	DERMAPHARM : Jefferies reiterates its Buy rating	ZD

Dermapharm Holding SE Provides Earnings Guidance for the Year 2020

November 16, 2020 at 12:00 pm IST

Dermapharm Holding SE provided earnings guidance for the year 2020. The management board continues to expect an increase of 12% to 15% in revenue.

Latest news about Dermapharm Holding SE

Jefferies lowers target for Dermapharm to 51 euros - 'Buy'	06/06	DP
DERMAPHARM : Jefferies reiterates its Buy rating	06/06	ZD
Drug manufacturer Dermapharm starts the new year with declines	15/05	DP
Dermapharm Holding SE Reports Earnings Results for the First Quarter Ended March 31, 2024	15/05	CI
WDH/Pharmaceuticals manufacturer Dermapharm starts the new year with declines	15/05	DP
DERMAPHARM : Berenberg keeps its Buy rating	04/04	ZD
Dermapharm Holding SE Reports Earnings Results for the Full Year Ended December 31, 2023	28/03	CI
Dpa-AFX Overview: COMPANIES from 14.03.2024 - 15:15	14/03	DP
Dermapharm looks cautiously into the future - missing Covid business	14/03	DP
DERMAPHARM : Berenberg reaffirms its Buy rating	07/12	ZD
DERMAPHARM : Berenberg reiterates its Buy rating	16/11	ZD
Dpa-AFX Overview: COMPANIES from 15.11.2023 - 15:15	15/11	DP
Dermapharm grows thanks to new subsidiary - nutritional supplements in demand	15/11	DP
DERMAPHARM : Jefferies reiterates its Buy rating	15/11	ZD
Dermapharm with leap in sales - growth driver Arkopharma	15/11	RE
Dermapharm Holding SE Reports Earnings Results for the Nine Months Ended September 30, 2023	15/11	CI
Dermapharm grows thanks to subsidiary Arkopharma and dietary supplements	15/11	DP
DERMAPHARM : Buy rating from Berenberg	19/23/19	ZD
DERMAPHARM : Berenberg maintains a Buy rating	21/23/21	ZD
Dermapharm Holding SE Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	29/23/29	CI
DERMAPHARM : Jefferies keeps its Buy rating	29/23/29	ZD
Dermapharm move to SDax top - Jefferies praises profitability	16/23/16	DP
Dermapharm becomes more optimistic after first half-year - share price jumps	16/23/16	DP
Jefferies leaves Dermapharm at 'Buy' - Target 65 euros	16/23/16	DP
DERMAPHARM : Jefferies reiterates its Buy rating	16/23/16	ZD

Dermapharm Holding SE is a Germany-based company engaged in manufacturing of patent-free branded pharmaceuticals. The Company operates through two segments: Branded pharmaceuticals and other healthcare products, which includes in-house development, in-house production, and distribution of branded pharmaceuticals and other healthcare products, and Parallel import business, which operates under the axicorp brand. It holds around 950 marketing authorizations for more than 250 active pharmaceutical ingredients, which are marketed as pharmaceuticals, dietary supplements or supplemental balanced diets. The Company offers its products through a number of brands, including Dekristol, Ampho Moronal, Keltican, Tromcardin, among others. It is active primarily in Germany, Switzerland and Austria. Additionally, it operates production facility in Germany. Trommsdorff & GmbH Co KG is a subsidiary of the Company.

Sector

Pharmaceuticals

Calendar

27/08/2024 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Dermapharm Holding SE

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

36 EUR

Average target price

50.12 EUR

Spread / Average Target

+39.24%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
DERMAPHARM HOLDING SE	-14.97%	207.68Cr
ELI LILLY AND COMPANY	+55.32%	82TCr
JOHNSON & JOHNSON	-6.75%	35TCr
MERCK & CO., INC.	+13.56%	31TCr
ABBVIE INC.	+10.68%	30TCr
ASTRAZENECA PLC	+16.57%	24TCr
ROCHE HOLDING AG	+2.04%	22TCr
NOVARTIS AG	+13.31%	22TCr
AMGEN INC.	+8.48%	17TCr
PFIZER, INC.	-2.81%	16TCr

Other Pharmaceuticals